Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

NCT04872478 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia

Interventions

DRUG: MRX-2843

Sponsor

Meryx, Inc.